Xiao Ying Meng
Director/Board Member bij BMC MEDICAL CO., LTD.
Profiel
Xiao Ying Meng is currently the Director at BMC Medical Co. Ltd.
since 2019 and the Non-Executive Director at TYK Medicines, Inc. since 2021.
Previously, she worked as a Member-Supervisory Board at Chengdu Bright Eye Hospital Co., Ltd.
from 2018 to 2022.
Dr. Meng holds a doctorate degree from The Pennsylvania State University, an undergraduate degree from Nanjing University, and a graduate degree from Nanjing University.
Actieve functies van Xiao Ying Meng
| Bedrijven | Functie | Begin |
|---|---|---|
| BMC MEDICAL CO., LTD. | Director/Board Member | 01-12-2019 |
TYK Medicines, Inc.
 TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Director/Board Member | 01-01-2021 |
Eerdere bekende functies van Xiao Ying Meng
| Bedrijven | Functie | Einde |
|---|---|---|
| CHENGDU BRIGHT EYE HOSPITAL CO., LTD. | Director/Board Member | 10-10-2022 |
Opleiding van Xiao Ying Meng
| The Pennsylvania State University | Doctorate Degree |
| Nanjing University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BMC MEDICAL CO., LTD. | Health Technology |
| CHENGDU BRIGHT EYE HOSPITAL CO., LTD. | Health Services |
| Bedrijven in privébezit | 1 |
|---|---|
TYK Medicines, Inc.
TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Health Technology |
